Logo image of PACB

PACIFIC BIOSCIENCES OF CALIF (PACB) Stock Fundamental Analysis

NASDAQ:PACB - Nasdaq - US69404D1081 - Common Stock - Currency: USD

1.13  +0.02 (+1.8%)

After market: 1.14 +0.01 (+0.88%)

Fundamental Rating

2

Taking everything into account, PACB scores 2 out of 10 in our fundamental rating. PACB was compared to 55 industry peers in the Life Sciences Tools & Services industry. PACB has a bad profitability rating. Also its financial health evaluation is rather negative. PACB is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year PACB has reported negative net income.
In the past year PACB has reported a negative cash flow from operations.
PACB had negative earnings in 4 of the past 5 years.
In the past 5 years PACB reported 4 times negative operating cash flow.
PACB Yearly Net Income VS EBIT VS OCF VS FCFPACB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

Looking at the Return On Assets, with a value of -24.58%, PACB is doing worse than 71.43% of the companies in the same industry.
Looking at the Return On Equity, with a value of -61.16%, PACB is doing worse than 73.21% of the companies in the same industry.
Industry RankSector Rank
ROA -24.58%
ROE -61.16%
ROIC N/A
ROA(3y)-19.98%
ROA(5y)-12.37%
ROE(3y)-53.57%
ROE(5y)-34.97%
ROIC(3y)N/A
ROIC(5y)N/A
PACB Yearly ROA, ROE, ROICPACB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

PACB has a Gross Margin of 24.85%. This is in the lower half of the industry: PACB underperforms 78.57% of its industry peers.
PACB's Gross Margin has declined in the last couple of years.
PACB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 24.85%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18.03%
GM growth 5Y-8.17%
PACB Yearly Profit, Operating, Gross MarginsPACB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

More info and screens

3

2. Health

2.1 Basic Checks

PACB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PACB has more shares outstanding
PACB has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, PACB has a worse debt to assets ratio.
PACB Yearly Shares OutstandingPACB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
PACB Yearly Total Debt VS Total AssetsPACB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

Based on the Altman-Z score of -2.29, we must say that PACB is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -2.29, PACB is doing worse than 83.93% of the companies in the same industry.
PACB has a Debt/Equity ratio of 1.28. This is a high value indicating a heavy dependency on external financing.
PACB's Debt to Equity ratio of 1.28 is on the low side compared to the rest of the industry. PACB is outperformed by 82.14% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.28
Debt/FCF N/A
Altman-Z -2.29
ROIC/WACCN/A
WACC5.9%
PACB Yearly LT Debt VS Equity VS FCFPACB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 7.48 indicates that PACB has no problem at all paying its short term obligations.
PACB has a Current ratio of 7.48. This is amongst the best in the industry. PACB outperforms 85.71% of its industry peers.
PACB has a Quick Ratio of 6.59. This indicates that PACB is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 6.59, PACB belongs to the best of the industry, outperforming 85.71% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.48
Quick Ratio 6.59
PACB Yearly Current Assets VS Current LiabilitesPACB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

4

3. Growth

3.1 Past

PACB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -35.54%.
The Revenue for PACB has decreased by -23.19% in the past year. This is quite bad
The Revenue has been growing by 11.12% on average over the past years. This is quite good.
EPS 1Y (TTM)-35.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-58.06%
Revenue 1Y (TTM)-23.19%
Revenue growth 3Y5.68%
Revenue growth 5Y11.12%
Sales Q2Q%-32.79%

3.2 Future

The Earnings Per Share is expected to grow by 12.21% on average over the next years. This is quite good.
PACB is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 15.03% yearly.
EPS Next Y55.63%
EPS Next 2Y27.69%
EPS Next 3Y19.58%
EPS Next 5Y12.21%
Revenue Next Year3.47%
Revenue Next 2Y12.14%
Revenue Next 3Y16.02%
Revenue Next 5Y15.03%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
PACB Yearly Revenue VS EstimatesPACB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M
PACB Yearly EPS VS EstimatesPACB Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PACB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PACB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PACB Price Earnings VS Forward Price EarningsPACB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PACB Per share dataPACB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PACB's earnings are expected to grow with 19.58% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.69%
EPS Next 3Y19.58%

More info and screens

0

5. Dividend

5.1 Amount

PACB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PACIFIC BIOSCIENCES OF CALIF

NASDAQ:PACB (5/2/2025, 8:16:19 PM)

After market: 1.14 +0.01 (+0.88%)

1.13

+0.02 (+1.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-13 2025-02-13/amc
Earnings (Next)05-08 2025-05-08/amc
Inst Owners84.93%
Inst Owner Change-2.45%
Ins Owners0.53%
Ins Owner Change18.05%
Market Cap339.05M
Analysts75.24
Price Target2.15 (90.27%)
Short Float %17.47%
Short Ratio4.56
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-64.98%
Min EPS beat(2)-133.89%
Max EPS beat(2)3.93%
EPS beat(4)1
Avg EPS beat(4)-75.73%
Min EPS beat(4)-169.73%
Max EPS beat(4)3.93%
EPS beat(8)3
Avg EPS beat(8)-34.87%
EPS beat(12)4
Avg EPS beat(12)-24.55%
EPS beat(16)6
Avg EPS beat(16)-18.86%
Revenue beat(2)0
Avg Revenue beat(2)-5.43%
Min Revenue beat(2)-6.61%
Max Revenue beat(2)-4.25%
Revenue beat(4)0
Avg Revenue beat(4)-8.98%
Min Revenue beat(4)-13.63%
Max Revenue beat(4)-4.25%
Revenue beat(8)3
Avg Revenue beat(8)0.28%
Revenue beat(12)4
Avg Revenue beat(12)-0.67%
Revenue beat(16)7
Avg Revenue beat(16)0.24%
PT rev (1m)-17.11%
PT rev (3m)-25.57%
EPS NQ rev (1m)0.1%
EPS NQ rev (3m)-4.93%
EPS NY rev (1m)2.08%
EPS NY rev (3m)-5.26%
Revenue NQ rev (1m)3.76%
Revenue NQ rev (3m)-16.42%
Revenue NY rev (1m)-0.96%
Revenue NY rev (3m)-14.02%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.2
P/FCF N/A
P/OCF N/A
P/B 0.67
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.64
EYN/A
EPS(NY)-0.73
Fwd EYN/A
FCF(TTM)-0.71
FCFYN/A
OCF(TTM)-0.69
OCFYN/A
SpS0.51
BVpS1.69
TBVpS-0.67
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -24.58%
ROE -61.16%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 24.85%
FCFM N/A
ROA(3y)-19.98%
ROA(5y)-12.37%
ROE(3y)-53.57%
ROE(5y)-34.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18.03%
GM growth 5Y-8.17%
F-Score2
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 1.28
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15.02%
Cap/Sales 4.02%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.48
Quick Ratio 6.59
Altman-Z -2.29
F-Score2
WACC5.9%
ROIC/WACCN/A
Cap/Depr(3y)74.27%
Cap/Depr(5y)63.44%
Cap/Sales(3y)7.21%
Cap/Sales(5y)5.5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-35.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-58.06%
EPS Next Y55.63%
EPS Next 2Y27.69%
EPS Next 3Y19.58%
EPS Next 5Y12.21%
Revenue 1Y (TTM)-23.19%
Revenue growth 3Y5.68%
Revenue growth 5Y11.12%
Sales Q2Q%-32.79%
Revenue Next Year3.47%
Revenue Next 2Y12.14%
Revenue Next 3Y16.02%
Revenue Next 5Y15.03%
EBIT growth 1Y16.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year40.63%
EBIT Next 3Y18.97%
EBIT Next 5Y16.5%
FCF growth 1Y20.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y20.49%
OCF growth 3YN/A
OCF growth 5YN/A